AR127431A1 - Compuestos novedosos - Google Patents
Compuestos novedososInfo
- Publication number
- AR127431A1 AR127431A1 ARP220102871A ARP220102871A AR127431A1 AR 127431 A1 AR127431 A1 AR 127431A1 AR P220102871 A ARP220102871 A AR P220102871A AR P220102871 A ARP220102871 A AR P220102871A AR 127431 A1 AR127431 A1 AR 127431A1
- Authority
- AR
- Argentina
- Prior art keywords
- compound
- formula
- pharmaceutically acceptable
- acceptable salt
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2115156.8A GB202115156D0 (en) | 2021-10-21 | 2021-10-21 | Novel compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR127431A1 true AR127431A1 (es) | 2024-01-24 |
Family
ID=78805918
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP220102871A AR127431A1 (es) | 2021-10-21 | 2022-10-21 | Compuestos novedosos |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US20240425511A1 (enExample) |
| EP (2) | EP4419527A1 (enExample) |
| JP (2) | JP2024539132A (enExample) |
| KR (1) | KR20240099274A (enExample) |
| CN (2) | CN119053600A (enExample) |
| AR (1) | AR127431A1 (enExample) |
| AU (1) | AU2022374050A1 (enExample) |
| CA (1) | CA3233255A1 (enExample) |
| DK (1) | DK4419526T3 (enExample) |
| ES (1) | ES3008687T3 (enExample) |
| FI (1) | FI4419526T3 (enExample) |
| GB (1) | GB202115156D0 (enExample) |
| HR (1) | HRP20250334T1 (enExample) |
| HU (1) | HUE070568T2 (enExample) |
| IL (1) | IL311922A (enExample) |
| LT (1) | LT4419526T (enExample) |
| MX (1) | MX2024004874A (enExample) |
| PL (1) | PL4419526T3 (enExample) |
| PT (1) | PT4419526T (enExample) |
| RS (1) | RS66620B1 (enExample) |
| SI (1) | SI4419526T1 (enExample) |
| SM (1) | SMT202500123T1 (enExample) |
| TW (1) | TW202334150A (enExample) |
| WO (2) | WO2023067356A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025077896A1 (zh) * | 2023-10-12 | 2025-04-17 | 上海湃隆生物科技有限公司 | 一种DNA聚合酶theta抑制剂及其应用 |
| CN118084767B (zh) * | 2024-04-02 | 2025-06-17 | 康龙化成手性医药技术(宁波)有限公司 | 一种外型-6-氟甲基-3-氮杂双环[3,1,0]己烷盐酸盐及其衍生物的合成方法 |
| WO2025214463A1 (zh) * | 2024-04-13 | 2025-10-16 | 正大天晴药业集团股份有限公司 | 含有三并环结构的化合物 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017062754A1 (en) | 2015-10-07 | 2017-04-13 | New York University | Compositions and methods for enhancing crispr activity by polq inhibition |
| EP4010080B1 (en) * | 2019-08-09 | 2023-09-27 | Artios Pharma Limited | Heterocyclic compounds for use in the treatment of cancer |
-
2021
- 2021-10-21 GB GBGB2115156.8A patent/GB202115156D0/en not_active Ceased
-
2022
- 2022-10-21 JP JP2024523601A patent/JP2024539132A/ja active Pending
- 2022-10-21 HR HRP20250334TT patent/HRP20250334T1/hr unknown
- 2022-10-21 DK DK22797829.3T patent/DK4419526T3/da active
- 2022-10-21 CN CN202280083817.2A patent/CN119053600A/zh active Pending
- 2022-10-21 IL IL311922A patent/IL311922A/en unknown
- 2022-10-21 US US18/699,286 patent/US20240425511A1/en active Pending
- 2022-10-21 HU HUE22797829A patent/HUE070568T2/hu unknown
- 2022-10-21 MX MX2024004874A patent/MX2024004874A/es unknown
- 2022-10-21 PT PT227978293T patent/PT4419526T/pt unknown
- 2022-10-21 CN CN202280070670.3A patent/CN118234728A/zh active Pending
- 2022-10-21 EP EP22802224.0A patent/EP4419527A1/en active Pending
- 2022-10-21 JP JP2024523445A patent/JP2024542949A/ja active Pending
- 2022-10-21 LT LTEPPCT/GB2022/052690T patent/LT4419526T/lt unknown
- 2022-10-21 KR KR1020247015701A patent/KR20240099274A/ko active Pending
- 2022-10-21 PL PL22797829.3T patent/PL4419526T3/pl unknown
- 2022-10-21 CA CA3233255A patent/CA3233255A1/en active Pending
- 2022-10-21 FI FIEP22797829.3T patent/FI4419526T3/fi active
- 2022-10-21 SI SI202230104T patent/SI4419526T1/sl unknown
- 2022-10-21 RS RS20250272A patent/RS66620B1/sr unknown
- 2022-10-21 WO PCT/GB2022/052690 patent/WO2023067356A1/en not_active Ceased
- 2022-10-21 ES ES22797829T patent/ES3008687T3/es active Active
- 2022-10-21 AR ARP220102871A patent/AR127431A1/es unknown
- 2022-10-21 SM SM20250123T patent/SMT202500123T1/it unknown
- 2022-10-21 WO PCT/GB2022/052689 patent/WO2023067355A1/en not_active Ceased
- 2022-10-21 US US18/701,963 patent/US20260124214A1/en active Pending
- 2022-10-21 TW TW111140009A patent/TW202334150A/zh unknown
- 2022-10-21 EP EP22797829.3A patent/EP4419526B1/en active Active
- 2022-10-21 AU AU2022374050A patent/AU2022374050A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20260124214A1 (en) | 2026-05-07 |
| JP2024542949A (ja) | 2024-11-19 |
| EP4419526B1 (en) | 2024-12-25 |
| GB202115156D0 (en) | 2021-12-08 |
| IL311922A (en) | 2024-06-01 |
| RS66620B1 (sr) | 2025-04-30 |
| CN119053600A (zh) | 2024-11-29 |
| EP4419526A1 (en) | 2024-08-28 |
| US20240425511A1 (en) | 2024-12-26 |
| HRP20250334T1 (hr) | 2025-06-06 |
| SMT202500123T1 (it) | 2025-05-12 |
| TW202334150A (zh) | 2023-09-01 |
| PL4419526T3 (pl) | 2025-04-22 |
| ES3008687T3 (en) | 2025-03-24 |
| EP4419527A1 (en) | 2024-08-28 |
| SI4419526T1 (sl) | 2025-05-30 |
| MX2024004874A (es) | 2024-05-06 |
| JP2024539132A (ja) | 2024-10-28 |
| PT4419526T (pt) | 2025-02-03 |
| CA3233255A1 (en) | 2023-04-27 |
| DK4419526T3 (da) | 2025-02-17 |
| LT4419526T (lt) | 2025-03-25 |
| AU2022374050A1 (en) | 2024-05-02 |
| FI4419526T3 (fi) | 2025-02-13 |
| WO2023067356A1 (en) | 2023-04-27 |
| WO2023067355A1 (en) | 2023-04-27 |
| HUE070568T2 (hu) | 2025-06-28 |
| KR20240099274A (ko) | 2024-06-28 |
| CN118234728A (zh) | 2024-06-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022012641A2 (pt) | Compostos tricíclicos substituídos | |
| MX2022006475A (es) | Compuestos triciclicos sustituidos. | |
| CL2022000271A1 (es) | Inhibidores de la fosfatasa shp2 de pirazolo(3,4-b)pirazina. | |
| PE20212303A1 (es) | Inhibidores aza-heterobiciclicos de mat2a y metodos de uso en el tratamiento de cancer | |
| CO2019009423A2 (es) | Inhibidores de mnk sustituidos con piperidina y métodos relacionados con los mismos | |
| WO2021147236A9 (zh) | 取代氨基丙酸酯类化合物在治疗SARS-CoV-2感染中的应用 | |
| CO2026005655A2 (es) | Inhibidor de pan-kras y uso del mismo en medicinas | |
| BR112022002496A2 (pt) | Compostos deuterados para uso no tratamento de câncer | |
| PE20181778A1 (es) | Derivados de indolina sustituidos como inhibidores de la replicacion viral del dengue | |
| ZA202408030B (en) | Tricyclic heterocyclic derivatives, compositions and uses thereof | |
| PH12022550338A1 (en) | 2-hydroxycycloalkane-1-carbamoyl derivatives | |
| CL2024001565A1 (es) | Compuestos macrocíclicos con actividad inhibidora de la farnesiltransferasa, composición que los comprende y su uso. | |
| PH12022550436A1 (en) | Alpha-d-galactopyranoside derivatives | |
| CL2011001860A1 (es) | Compuestos derivados de indol; procedimiento de preparacion de dichos compuestos; composicion y combinacion farmaceutica; y uso en el tratamiento del cancer. | |
| MX2022003617A (es) | Derivados heterociclicos, composiciones farmaceuticas y su uso en el tratamiento o mejora del cancer. | |
| SA519402103B1 (ar) | 1,6-naphthyridine مشتقات 1، 6 نفثيرايدين CDK4/6 على شكل مثبط | |
| AR117844A1 (es) | Derivados de tiazolopiridina como antagonistas del receptor de adenosina | |
| MX2025012818A (es) | Derivados de heterociclicos triciclicos, composiciones y usos de estos | |
| MX2024004874A (es) | Compuestos heterociclicos para uso en el tratamiento de cancer. | |
| DOP2022000107A (es) | Derivados de 1,2,4oxadiazol como agonistas del receptor hepático x | |
| UY39865A (es) | Pirazin-2-carboxamidas sustituidas como inhibidores de hpk1 para el tratamiento del cáncer | |
| PE20181450A1 (es) | Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer | |
| MX2020008360A (es) | Forma cristalina de bictegravir sodico. | |
| AR107937A1 (es) | Compuestos de cinolin-4-amina y su uso en el tratamiento del cáncer | |
| DOP2022000073A (es) | Derivados de 2-azaspiro[3,4]octano como agonistas de m4 |